High dose ascorbic acid does not reverse central sympathetic overactivity in chronic heart failure.
Summary What is known and Objective: The increased central sympathetic activity typically associated with chronic heart failure (CHF) is probably mediated by formation of reactive oxygen species (ROS) in the brain. Our objective was to undertake a trial to test our hypothesis that administration of...
| Published in: | Journal of Clinical Pharmacy & Therapeutics Vol. 36; no. 5; pp. 546 - 553 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | research tables/charts randomized controlled trial Journal Article |
| Published: |
Wiley-Blackwell
Oct2011
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104685566&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104685566 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 02694727 EV4 jtl: Journal of Clinical Pharmacy & Therapeutics issn: 02694727 maglogo: Y pubinfo: dt: Oct2011 vid: 36 iid: 5 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 104685566 65430244 10.1111/j.1365-2710.2010.01205.x NLM21916906 104685566 ppf: 546 ppct: 7 formats: fmt: @attributes: type: P tig: atl: High dose ascorbic acid does not reverse central sympathetic overactivity in chronic heart failure. aug: au: Gomes, M. E. El Messaoudi, S. Lenders, J. W. M. Bellersen, L. Verheugt, F. W. A. Smits, P. Tack, C. J. affil: Department of Cardiology sug: subj: Ascorbic Acid Administration and Dosage Heart Failure Drug Therapy Sympathetic Nervous System Drug Effects Prospective Studies Randomized Controlled Trials Double-Blind Studies Crossover Design Ascorbic Acid Blood Heart Rate Variability Norepinephrine Blood Human Catecholamines Blood Electrodiagnosis Data Analysis Software Chromatography, High Pressure Liquid Power Analysis T-Tests Parametric Statistics Matched-Pair Analysis Nonparametric Statistics Wilcoxon Rank Sum Test Pearson's Correlation Coefficient Male Female Middle Age Treatment Outcomes Reactive Oxygen Species Drug Effects Middle Aged: 45-64 years Male Female ab: Summary What is known and Objective: The increased central sympathetic activity typically associated with chronic heart failure (CHF) is probably mediated by formation of reactive oxygen species (ROS) in the brain. Our objective was to undertake a trial to test our hypothesis that administration of the well-known antioxidant and ROS scavenger ascorbic acid, would reverse or reduce the sympathetic overactivity in CHF patients. Methods: In a prospective, randomized, placebo-controlled, double-blind, cross-over trial, 11 CHF patients were treated with ascorbic acid 2 g/day or placebo for 3 days. At the end of each treatment period, sympathetic nervous system activity was measured by microneurography for direct muscle sympathetic nerve activity (MSNA) recording, analysis of heart rate variability (HRV) and measurement of plasma norepinephrine concentrations. Results: During ascorbic acid administration, plasma vitamin C levels were higher than during placebo (74·9 ± 6·0 μmol/L vs. 54·8 ± 4·6 μmol/L, P = 0·03). Ascorbic acid had no effect on sympathetic activity: MSNA (ascorbic acid: 66·8 ± 3·3 vs. placebo 66·9 ± 3·2 bursts/100 beats, P = 0·98). In addition, HRV and plasma norepinephrine levels did not differ. What is new and Conclusion: Short-term administration of the antioxidant ascorbic acid in CHF patients does not reverse the increased sympathetic activity as measured by microneurography, HRV and plasma norepinephrine levels. The use of higher oral dosages seems not feasible due to accompanying side effects. pubtype: Academic Journal doctype: research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|